TB-500 has a relatively long half-life estimated at several days, which allows for less frequent dosing compared to shorter-acting peptides. This extended half-life contributes to sustained tissue repair effects. Twice-weekly dosing is common, though some protocols use once-weekly administration during maintenance phases.
TB-4 pharmacokinetics